Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Brigham and Women's Hospital, 45 Francis Street, ASB-2, Boston, MA 02115, USA; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.
Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Brigham and Women's Hospital, 45 Francis Street, ASB-2, Boston, MA 02115, USA; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Boston, MA, USA.
Hematol Oncol Clin North Am. 2021 Oct;35(5):913-931. doi: 10.1016/j.hoc.2021.05.004. Epub 2021 Jul 7.
Squamous cell carcinoma of the oropharynx (OPC) consists of human papillomavirus (HPV)-negative disease caused by tobacco and alcohol use, and HPV-positive disease caused by the sexually transmitted infection HPV. These entities have unique but overlapping risk factors, epidemiologic trends, staging systems, and survival outcomes. HPV-positive tumor status confers a significant survival benefit compared with HPV-negative disease. OPC treatment entails a combination of surgery, radiation, and chemotherapy. Ongoing trials will determine whether treatment of HPV-related disease may be safely deintensified to decrease morbidity. Emerging HPV-related biomarkers are under study as tools to inform screening, diagnosis, treatment, and surveillance for HPV-positive OPC.
口咽鳞状细胞癌（OPC）包括由烟草和酒精使用引起的人乳头瘤病毒（HPV）阴性疾病，以及由性传播感染 HPV 引起的 HPV 阳性疾病。这些实体具有独特但重叠的危险因素、流行病学趋势、分期系统和生存结果。与 HPV 阴性疾病相比，HPV 阳性肿瘤状态可显著提高生存率。OPC 的治疗需要手术、放疗和化疗的结合。正在进行的试验将确定是否可以安全地降低 HPV 相关疾病的治疗强度，以降低发病率。新兴的 HPV 相关生物标志物正被研究作为工具，以告知 HPV 阳性 OPC 的筛查、诊断、治疗和监测。
